SCHEMBL10658601

SCHEMBL10658601

CC(N)C(=O)N1CCCC1C(=O)N1CCCC1C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE P12821 7/20 0.57
REN P00797 4/20 0.57
KDM4E B2RXH2 1/20 0.57
F2 P00734 1/20 0.57
LMNA P02545 1/20 0.57
LTA4H P09960 1/20 0.57
MAPT P10636 1/20 0.57
PEPD P12955 1/20 0.57
ALOX15 P16050 1/20 0.57
PTGS1 P23219 1/20 0.57
HTR2A P28223 1/20 0.57
PTGS2 P35354 1/20 0.57
HRH1 P35367 1/20 0.57
THPO P40225 1/20 0.57
PMP22 Q01453 1/20 0.57
HSD17B10 Q99714 1/20 0.57
ACE2 Q9BYF1 1/20 0.57
DPP4 P27487 3/20 0.53
FAP Q12884 2/20 0.53
DPP7 Q9UHL4 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31401996 1.00 ACE (0.57) ACERENKDM4EF2LMNA
SCHEMBL10653331 1.00 ACE (0.57) ACERENKDM4EF2LMNA
SCHEMBL10829256 1.00 ACE (0.57) ACERENKDM4EF2LMNA
SCHEMBL31401997 1.00 ACE (0.57) ACERENKDM4EF2LMNA
SCHEMBL30139015 1.00 ACE (0.57) ACERENKDM4EF2LMNA
SCHEMBL593691 0.94 ACE (0.64) ACERENKDM4EF2LMNA
SCHEMBL8316371 0.94 ACE (0.64) ACERENKDM4EF2LMNA
SCHEMBL2115246 0.94 ACE (0.64) ACERENKDM4EF2LMNA
SCHEMBL9164453 0.94 ACE (0.64) ACERENKDM4EF2LMNA
SCHEMBL2115244 0.94 ACE (0.64) ACERENKDM4EF2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 4302 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122031713-A Preparation method and application of linker medicine and antibody-medicine conjugate thereof 乐普生物科技股份有限公司 2026-05-15 CN claimed
US-12622948-B2 GLP-1/GIP dual agonists SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2026-05-12 US claimed
US-20240424063-A1 LONG ACTING GLP-1/GIP DUAL AGONISTS SUN PHARMACEUTICAL IND LTD (IN) 2024-12-26 US claimed
US-20240400613-A1 GLP-1/GIP DUAL AGONISTS SUN PHARMACEUTICAL IND LTD (IN) 2024-12-05 US claimed
WO-2024160176-A1 LINKER DRUG, AND PREPARATION METHOD AND USE OF ANTIBODY-DRUG CONJUGATE THEREOF 上海美雅珂生物技术有限责任公司 2024-08-08 WO claimed
US-20230241178-A1 LONG ACTING GLP-1/GIP DUAL AGONISTS SUN PHARMACEUTICAL IND LTD (IN) 2023-08-03 US claimed
EP-4204440-A1 GLP-1/GIP DUAL AGONISTS Sun Pharmaceutical Industries Limited (IN) 2023-07-05 EP claimed
CN-116171164-A GLP-1/GIP dual agonists 太阳医药工业有限公司 2023-05-26 CN claimed
EP-4146248-A1 LONG ACTING GLP-1/GIP DUAL AGONISTS Sun Pharmaceutical Industries Limited (IN) 2023-03-15 EP claimed
CN-115768460-A Long-acting GLP-1/GIP dual agonists 太阳医药工业有限公司 2023-03-07 CN claimed
US-20220313770-A1 IMMUNOTHERAPY FOR ANGIOGENIC DISEASE INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) 2022-10-06 US claimed
CN-114949171-A Immunotherapy of angiogenic diseases 株式会社癌免疫研究所 2022-08-30 CN claimed
US-11413322-B2 Immunotherapy for angiogenic disease INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) 2022-08-16 US claimed
US-11369656-B2 Immunotherapy for angiogenic disease INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) 2022-06-28 US claimed
CN-108064163-B Immunotherapy of angiogenic diseases 株式会社癌免疫研究所 2022-06-10 CN claimed
WO-2022079639-A1 GLP-1/GIP DUAL AGONISTS SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2022-04-21 WO claimed
JP-61053298-A None JP disclosed
CN-122075733-A Preparation method and application of linker medicine and antibody-medicine conjugate thereof 2026-05-26 CN disclosed
JP-S6153298-A AMINO ACID DERIVATIVE AND HYPOTENSOR CONTAINING SAME AJINOMOTO CO INC 1986-03-17 JP disclosed
EP-0173510-A2 Tripeptide derivatives for use as anti-hypertensive agents AJINOMOTO CO., INC. (JP) 1986-03-05 EP disclosed